Results 151 to 160 of about 33,638 (296)
Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality [PDF]
, 1991 WN Patton +3 more
openalex +1 more source
Clinical Pharmacology in Drug Development, Volume 14, Issue 4, Page 311-323, April 2025.Abstract Rusfertide, a peptide hepcidin mimetic, has shown efficacy in polycythemia vera. This trial investigated the multiple‐dose pharmacokinetics, pharmacodynamics, and safety of once‐weekly rusfertide 60 mg for 5 weeks in healthy subjects. Subjects were randomized to subcutaneous injection in the abdomen, upper arm, or thigh. Eighteen subjects were
Nishit B. Modi +2 more
wiley +1 more source
Intraperitoneal chemotherapy with cytosine arabinoside in agnogenic myelofibrosis with myeloid metaplasia and ascites due to peritoneal extramedullary hematopoiesis [PDF]
, 1993 Robert Stahl +2 more
openalex +1 more source
Reticulin‐Free Quantitation of Bone Marrow Fibrosis in MPNs: Utility and Applications
eJHaem, Volume 6, Issue 2, April 2025.ABSTRACT Background Automated quantitation of marrow fibrosis promises to improve fibrosis assessment in myeloproliferative neoplasms (MPNs). However, analysis of reticulin‐stained images is complicated by technical challenges within laboratories and variability between institutions.
Hosuk Ryou +9 more
wiley +1 more source
Myelofibrosis with portal hypertension: a report of 2 cases.
, 1984 Shoichi Matsutani +2 more
openalex +2 more sources
Treatment of myelofibrosis and primary erythermalgia [PDF]
, 1993 Şînasi Özsoylu
openalex +1 more source
eJHaem, Volume 6, Issue 2, April 2025.ABSTRACT Introduction Ruxolitinib was the first JAK2 inhibitor approved for the treatment of primary and secondary myelofibrosis. It is currently used worldwide as first‐line therapy for advanced disease (intermediate‐2 and high‐risk) and is effective in polycythaemia vera (PV) and essential thrombocythaemia (ET), but not funded for this indication in ...
Liesl A. Butler +3 more
wiley +1 more source